An Act Implementing The Governor's Budget Recommendations For Health And Human Services.
HB 5040 is a budget-implementation bill for the Department of Social Services and broader health and human services programs. It makes three main changes effective July 1, 2026. First, it revises the state-administered general assistance (SAGA) cash assistance statute to set a single monthly cash benefit of $269 for eligible recipients, replacing the prior tiered structure for unemployable and transitional persons. It also preserves the rule that people cannot receive SAGA cash assistance if they are eligible for another state or federal cash assistance program, and keeps the existing boarding-facility standard subject to annual increases.
Second, the bill changes Medicaid pharmacy rules by requiring prior authorization for nonpreferred drugs on preferred drug lists, while creating an exception for mental-health-related drugs that have already been filled or refilled at least once in the prior year. Prior authorization approvals for drugs not on a preferred list would last one year. The bill also removes language stating that antiretroviral drugs may not be placed on preferred drug lists. Third, it authorizes the Commissioner of Social Services to review high-cost outpatient prescription drugs covered by Medicaid, either directly or through a contractor, using comparative effectiveness criteria such as clinical outcomes, pricing, utilization, and therapeutic value, and to share the results to support supplemental rebate negotiations.
The bill’s impact on state law is to update Connecticut’s cash assistance and Medicaid drug-management statutes, giving the Department of Social Services more tools to control program costs and negotiate drug rebates. It affects low-income individuals receiving SAGA assistance, Medicaid enrollees using prescription drugs, pharmacies, drug manufacturers, and potentially multistate drug purchasing collaboratives. It also creates a formal state process for evaluating expensive outpatient drugs based on cost and clinical value.
The general sentiment around the bill appears strongly favorable in committee, as reflected by the 23-0 Joint Favorable Substitute vote. No committee transcript was provided, but the unanimous vote suggests broad support for the budget-related health and human services changes, including the pharmacy management and cost-containment provisions.
The main points of contention likely center on the pharmacy provisions. The removal of the explicit protection for antiretroviral drugs from preferred drug lists could raise concerns among HIV/AIDS advocates and patient groups, while the prior authorization requirements and comparative effectiveness reviews may be viewed by some as administrative barriers or cost controls that could affect access to medications. At the same time, the mental-health-drug exception indicates an effort to preserve continuity of care for patients already stabilized on treatment.
HB 5040 amends Connecticut’s SAGA cash assistance statute and Medicaid prescription drug management provisions, while adding a new authority for the Department of Social Services to review high-cost outpatient drugs and use those findings in rebate negotiations. It directly affects cash assistance recipients, Medicaid beneficiaries, pharmacies, drug manufacturers, and state purchasing and rebate arrangements.
The bill appears to have broad support, as shown by the unanimous 23-0 Joint Favorable Substitute vote in the Human Services Committee. The available record suggests the measure was treated as a routine budget-implementation bill with cost-management and program-administration changes, rather than a highly divisive policy proposal.
The most likely areas of disagreement are the prescription drug provisions, especially the prior authorization rules and the deletion of the language excluding antiretroviral drugs from preferred drug lists. Those changes could concern patient advocates, HIV/AIDS advocates, and providers worried about access and continuity of care, while supporters may view them as tools to control Medicaid spending and improve rebate leverage. The SAGA cash assistance change is less visibly contentious in the record, but it reduces the prior tiered benefit structure and may draw concern from advocates for low-income adults.